Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bortezomib - Takeda Oncology/Janssen-Cilag

Drug Profile

Bortezomib - Takeda Oncology/Janssen-Cilag

Alternative Names: JNJ-26866138; LDP-341; MG-341; MLN-341; NSC-681239; PS 0341; PS-341; Velcade

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer Bayer; Childrens Mercy Hospital Kansas City; Dana-Farber Cancer Institute; Duke University; Erasmus MC; Genentech; Hoosier Cancer Research Network; HOVON Foundation; Indiana University; Janssen Pharmaceutical KK; Janssen Research & Development; Janssen-Cilag; Johnson & Johnson; Merck Sharp & Dohme; Millennium; Millennium Pharmaceuticals; New York University School of Medicine; Singapore General Hospital; Takeda Oncology; Teva Pharmaceutical Industries; University of Michigan Comprehensive Cancer Center; Weill Cornell Medical College
  • Class Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules
  • Mechanism of Action Apoptosis stimulants; NF-kappa B inhibitors; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Non-Hodgkin's lymphoma; Multiple myeloma; Mantle-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mantle-cell lymphoma; Multiple myeloma; Waldenstrom's macroglobulinaemia
  • Registered B-cell lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II Glioma; Graft-versus-host disease; Hodgkin's disease; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Acute myeloid leukaemia
  • Preregistration Submission Withdrawal Follicular lymphoma
  • No development reported Malignant melanoma; Neuroblastoma; Pancreatic cancer
  • Discontinued Adenocarcinoma; Amyloid light-chain amyloidosis; Cerebral ischaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Non-small cell lung cancer; Prostate cancer; Rheumatoid arthritis; T-cell prolymphocytic leukaemia

Most Recent Events

  • 17 Jun 2018 Janssen-Cilag completes a phase III trial for Multiple myeloma (First-line therapy, Combination therapy) in Italy (IV)
  • 07 Jun 2018 Millennium Pharmaceuticals completes a phase II trial in Lymphoma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT00439556)
  • 02 May 2018 Millennium Pharmaceuticals completes a phase II trial in Hodgkin's disease (Combination therapy, Second-line therapy or greater, In adolescents, In the elderly, In adults) in USA (IV) (NCT00967369)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top